C66

C66 is a synthetic curcumin analog developed by Wenzhou Medical University, primarily investigated for the treatment of diabetic kidney disease (DKD). It functions as a potent anti-inflammatory and antioxidant agent by inhibiting the c-Jun N-terminal kinase (JNK) signaling pathway. Preclinical studies indicate that C66 suppresses the activation of the NLRP3 inflammasome and reduces the expression of pro-inflammatory cytokines and fibrotic markers in the kidneys. By mitigating oxidative stress and inflammation, C66 aims to prevent or slow the progression of renal damage associated with diabetes. It is currently undergoing Phase I clinical evaluation in China to assess its safety, tolerability, and pharmacokinetics in healthy participants.

Other names

(2E,6E)-2,6-bis(2-fluorobenzylidene)cyclohexanone